AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
What's in Store for Merck in 2019 After a Solid Run in '18?
by Zacks Equity Research
Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
Moderna (MRNA) Announces Pipeline Progress, Shares Rise
by Zacks Equity Research
Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff
by Zacks Equity Research
Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate
by Zacks Equity Research
Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.
Why the Earnings Surprise Streak Could Continue for Astrazeneca (AZN)
by Zacks Equity Research
Astrazeneca (AZN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Immunomedics Enters Into Supply Deal for Breast Cancer Drug
by Zacks Equity Research
Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.
Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019
by Kinjel Shah
J&J's (JNJ) stock has declined more than 14% since Reuters reported that it knew for decades that its baby powders contained asbestos. It is better to avoid the stock and invest in these three big drug stocks instead.
The Zacks Analyst Blog Highlights: Procter & Gamble, Oracle, United Parcel Service, FedEx and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Oracle, United Parcel Service, FedEx and AstraZeneca
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations
by Zacks Equity Research
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.
Top Research Reports for Procter & Gamble, Oracle & United Parcel Service
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Oracle (ORCL) and United Parcel Service (UPS).
AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
by Zacks Equity Research
Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.
BMY vs. AZN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
Merck to Acquire Europe's Antelliq Group for $2.4 Billion
by Zacks Equity Research
Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Novartis Presents Additional Data on Breast Cancer Candidate
by Zacks Equity Research
Novartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer. The study scripts success in PFS.
AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi monotherapy and combination therapy fail to meet overall survival endpoint in phase III EAGLE study.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
Inovio (INO) to Receive Milestone Payment From AstraZeneca
by Zacks Equity Research
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%
by Zacks Equity Research
Glaxo (GSK) announces definitive deal to buy TESARO.
TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer
by Zacks Equity Research
TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.
Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease
by Zacks Equity Research
AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs